GPX4 and neoplasm: In combination with dabrafenib and trametinib, ferrostatin-1 enhances tumor growth of xenografted mice bearing A375GPX4−/− cells, while ferrostatin-1 withdrawal results in inhibiting the growth of GPX4−/− tumors (Hangauer et al., 2017).